[HTML][HTML] Aging and age‐related diseases: from mechanisms to therapeutic strategies

Z Li, Z Zhang, Y Ren, Y Wang, J Fang, H Yue, S Ma… - Biogerontology, 2021 - Springer
Aging is a physiological process mediated by numerous biological and genetic pathways,
which are directly linked to lifespan and are a driving force for all age-related diseases …

Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus

M Foretz, B Guigas, B Viollet - Nature Reviews Endocrinology, 2019 - nature.com
Despite its position as the first-line drug for treatment of type 2 diabetes mellitus, the
mechanisms underlying the plasma glucose level-lowering effects of metformin (1, 1 …

GDF15 mediates the effects of metformin on body weight and energy balance

AP Coll, M Chen, P Taskar, D Rimmington, S Patel… - Nature, 2020 - nature.com
Metformin, the world's most prescribed anti-diabetic drug, is also effective in preventing type
2 diabetes in people at high risk,. More than 60% of this effect is attributable to the ability of …

Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications

J Feng, X Wang, X Ye, I Ares, B Lopez-Torres… - Pharmacological …, 2022 - Elsevier
Metformin is the oldest and most commonly used first-line antidiabetic drug because of its
good clinical efficacy, high safety, low cost and easy access. At the same time, in recent …

[HTML][HTML] Metformin triggers a kidney GDF15-dependent area postrema axis to regulate food intake and body weight

SY Zhang, K Bruce, Z Danaei, RJW Li, DR Barros… - Cell Metabolism, 2023 - cell.com
Metformin, the most widely prescribed medication for obesity-associated type 2 diabetes
(T2D), lowers plasma glucose levels, food intake, and body weight in rodents and humans …

Metformin as anti-aging therapy: is it for everyone?

AA Soukas, H Hao, L Wu - Trends in Endocrinology & Metabolism, 2019 - cell.com
Metformin is the most widely prescribed oral hypoglycemic medication for type 2 diabetes
worldwide. Metformin also retards aging in model organisms and reduces the incidence of …

[HTML][HTML] Gut microbiota of patients with type 2 diabetes and gastrointestinal intolerance to metformin differs in composition and functionality from tolerant patients

CM Díaz-Perdigones, A Muñoz-Garach… - Biomedicine & …, 2022 - Elsevier
Objective Metformin modifies the gut microbiome in type 2 diabetes and gastrointestinal
tolerance to metformin could be mediated by the gut microbiome. Methods We enrolled 35 …

A randomised, double‐blind, placebo‐controlled trial of metformin on myocardial efficiency in insulin‐resistant chronic heart failure patients without diabetes

AH Larsen, N Jessen, H Nørrelund… - European journal of …, 2020 - Wiley Online Library
Aims The present study tested the hypothesis that metformin treatment may increase
myocardial efficiency (stroke work/myocardial oxygen consumption) in insulin‐resistant …

Gastrointestinal adverse events of metformin treatment in patients with type 2 diabetes mellitus: A systematic review, meta-analysis and meta-regression of …

K Nabrdalik, K Skonieczna-Żydecka, K Irlik… - Frontiers in …, 2022 - frontiersin.org
Introduction Metformin is the first choice drug in the treatment of type 2 diabetes mellitus but
its administration may be linked to gastrointestinal adverse events limiting its use. Objectives …

Metformin: A prospective alternative for the treatment of chronic pain

GDC Baeza-Flores, CG Guzmán-Priego… - Frontiers in …, 2020 - frontiersin.org
Metformin (biguanide) is a drug widely used for the treatment of type 2 diabetes. This drug
has been used for 60 years as a highly effective antihyperglycemic agent. The search for the …